Aclaris Therapeutics, Inc. (FRA:8AT)

Germany · Delayed Price · Currency is EUR

2.713

+0.051 (1.92%)

Feb 20, 2026, 4:00 PM EST

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
Contract Research	15.96M	19.58M	17.01M	13.45M	13.32M
Contract Research Growth	-18.50%	15.13%	26.46%	0.96%	-20.83%
Therapeutics	16.18M	28.21M	25.36M	932.00K	696.00K
Therapeutics Growth	-42.66%	11.27%	2620.60%	33.91%	-
Intersegment Elimination	-13.42M	-16.54M	-12.61M	-7.62M	-7.53M
Total	18.72M	31.25M	29.75M	6.76M	6.48M
Total Growth	-40.09%	5.03%	340.05%	4.30%	53.35%

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018	Dec '17 Dec 31, 2017	Dec '16 Dec 31, 2016	Dec '15 Dec 31, 2015
United States	18.72M	31.25M	29.75M	6.76M	6.48M
United States Growth	-40.09%	5.03%	340.05%	4.30%	53.35%
Total	18.72M	31.25M	29.75M	6.76M	6.48M
Total Growth	-40.09%	5.03%	340.05%	4.30%	53.35%

Source: S&P Global Market Intelligence.